Numis Securities reaffirmed their buy rating on shares of Indivior (LON:INDV) in a research report report published on Thursday morning. The firm currently has a GBX 640 ($8.57) price objective on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on the company. Jefferies Group upped their price objective on Indivior from GBX 490 ($6.56) to GBX 540 ($7.23) and gave the stock a buy rating in a research note on Friday, August 11th. Citigroup upgraded Indivior to a buy rating and upped their price objective for the stock from GBX 280 ($3.75) to GBX 490 ($6.56) in a research note on Wednesday, November 8th. Morgan Stanley upped their price objective on Indivior from GBX 320 ($4.29) to GBX 410 ($5.49) and gave the stock an equal weight rating in a research note on Thursday, November 9th. Royal Bank Of Canada restated an outperform rating and set a GBX 470 ($6.29) price objective on shares of Indivior in a research note on Thursday, August 3rd. Finally, Stifel Nicolaus restated a buy rating and set a GBX 400 ($5.36) price objective on shares of Indivior in a research note on Friday, September 15th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of GBX 472.43 ($6.33).

Shares of Indivior (LON:INDV) opened at GBX 386.93 ($5.18) on Thursday. Indivior has a 1-year low of GBX 246.50 ($3.30) and a 1-year high of GBX 421.50 ($5.64).

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/12/03/indivior-indv-earns-buy-rating-from-numis-securities.html.

About Indivior

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior (LON:INDV)

Receive News & Stock Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related stocks with our FREE daily email newsletter.